Ignite Creation Date:
2025-12-24 @ 2:39 PM
Ignite Modification Date:
2026-02-24 @ 5:04 PM
Study NCT ID:
NCT06445959
Status:
RECRUITING
Last Update Posted:
2025-10-24
First Post:
2024-05-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-08-29
Start Date Type:
ACTUAL
Primary Completion Date:
2027-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-31
First Submit QC Date:
None
Study First Post Date:
2024-06-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-23
Last Update Post Date:
2025-10-24
Last Update Post Date Type:
ESTIMATED